Clinical trial
Bifeprunox in the Treatment of Schizophrenia
NCT00193713 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00193713 |
|---|---|
| Title | Bifeprunox in the Treatment of Schizophrenia |
| Official title | A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003) |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | bifeprunox |
| Start date | May 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 16, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: